Correlates of osteoprotegerin levels in women and men.
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Osteoprotegerin (OPG) is a potent antiresorptive molecule that binds the final effector for osteoclastogenesis, receptor activator of NF-kappaB ligand (RANK-L). OPG production is regulated by a number of cytokines and hormones, including sex steroids, but there are few data on age and gender effects on circulating serum OPG levels, as well as possible relationships between OPG levels and bone turnover markers or bone mineral density (BMD). Thus, we measured serum OPG levels in an age-stratified, random sample of men (n = 346 age range, 23-90 years) and women (n = 304; age range 21-93 years) and related them to sex steroid levels, bone turnover markers and BMD. Serum OPG levels increased with age in both men (R = 0.39, p < 0.001) and women (R = 0.18, p < 0.01). Premenopausal women had higher OPG levels than men under age 50 years (171 +/- 6 pg/ml vs 134 +/- 6 pg/ml, respectively, p < 0.001), whereas serum OPG levels were no different in postmenopausal women compared with men = 50 years (195 +/- 7 pg/ml vs 188 +/- 7 pg/ml, respectively, p = 0.179). OPG levels correlated inversely with serum bioavailable testosterone levels in men = 50 years (R = -0.27, p < 0.001), but no associations were present with either estrogen or testosterone levels in the women. In the men, there was a trend for OPG levels to be associated positively with bone resorption markers and inversely with BMD. Collectively, the gender difference in OPG levels suggests that sex steroids may regulate OPG production in vivo, as has been found in vitro. Moreover, OPG production may also rise with increases in bone turnover, probably as a homeostatic mechanism to limit bone loss. Further studies directly testing these hypotheses should provide additional insights into the potential role of OPG in bone loss related to aging and sex steroid deficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Residual estrogen levels after the menopause correlate with bone density and fracture risk, yet the relationship of estrogen levels with serum OPG levels in postmenopausal women has been inconsistent across studies, with some supporting a weak relationship (375) and others no relationship (373, 379) or a negative correlation (381).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [373]
In the citing paper
“There is general agreement that OPG levels increase after the menopause (373, 379 -381) and with GnRH agonist therapy (382), both conditions of low estrogen levels.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [373]
In the citing paper
“As with women, serum OPG levels increase with age in men (372,373,376,380,381,391,392).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [373]
In the citing paper
“the evidence is conflicting about an association between markers of bone turnover and circulating OPG because some studies report an association (154,372,375) or an association only among osteoporotic women (384), and others report no association (373,379).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [373]
In the citing paper
“Serum OPG levels have been found to be positively related to BMD (375, 379), negatively related to BMD (374, 383), or unrelated to BMD (372, 373) in postmenopausal women.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [373]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439 · cited 5×
“Since it is at present unclear what proportion of circulating OPG is monomeric, dimeric or bound to RANK-L [10,24], it seems reasonable to use an assay that detects all forms of circulating OPG.”
BackgroundInfluentialSelf-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130 · cited 3×
“body and a rabbit polyclonal antibody for detection (Amgen, Thousand Oaks, CA) [3].”
BackgroundMethodSelf-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,228 · cited 5×
“Since it is at present unclear what proportion of circulating OPG is monomeric, dimeric or bound to RANK-L [10,24], it seems reasonable to use an assay that detects all forms of circulating OPG.”
BackgroundInfluentialOsteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.
Bucay, N., Sarosi, I., Dunstan, C. R., Morony, S., Tarpley, J., Capparelli, C., Scully, S., Tan, H. L., Xu, W., Lacey, D. L., et al. (1998) · Genes & Development · doi:10.1101/gad.12.9.1260 · Cited by 2,483 · cited 1×
“It is one of the most potent antiresorptive agents known, since transgenic mice overexpressing OPG have profound osteosclerosis and a virtual absence of osteoclasts [3] and, conversely, OPG knockout mice have marked osteopenia and increased numbers of osteoclasts [4,5].”
BackgroundSelf-citationHistory of the Rochester Epidemiology Project
Melton, L. J. (1996) · Mayo Clinic Proceedings · doi:10.4065/71.3.266 · Cited by 1,443 · cited 1×
“Subjects were recruited from age-stratified random samples of Rochester, Minnesota, men and women selected using the medical records linkage system of the Rochester Epidemiology Project [14].”
MethodHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Boyle, W. J., & Riggs, B. L. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.2 · Cited by 1,173 · cited 1×
“OPG production by osteoblastic cells is regulated by a number of cytokines and hormones, including sex steroids [6].”
BackgroundSelf-citationHofbauer, L. C., Khosla, S., Dunstan, C. R., Lacey, D. L., Spelsberg, T. C., & Riggs, B. L. (1999) · Endocrinology · doi:10.1210/endo.140.9.7131 · Cited by 692 · cited 2×
“Thus, several studies have found that estrogen (E) increases OPG production [7,8], whereas testosterone (T) tends to inhibit OPG mRNA and protein levels in osteoblastic cells [9].”
BackgroundSelf-citationBrowner, W. S., Lui, L.-Y., & Cummings, S. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7192 · Cited by 506 · cited 2×
“[11] did not find any association between serum OPG levels and either BMD or fractures in a cohort of postmenopausal women.”
BackgroundYano, K., Tsuda, E., Washida, N., Kobayashi, F., Goto, M., Harada, A., Ikeda, K., Higashio, K., & Yamada, Y. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.4.518 · Cited by 363 · cited 9×
“[10] did note a positive association between serum OPG levels and markers of bone turnover and a negative association between OPG and BMD in postmenopausal women, although they did not report comparable data in men.”
BackgroundResultInfluentialDelmas, P. D., Stenner, D., Wahner, H. W., Mann, K. G., & Riggs, B. L. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110882 · Cited by 353 · cited 1×
“Bone formation was assessed by serum osteocalcin, measured by RIA (interassay CV 56%) [18] as well as by serum bone-specific alkaline phosphatase (BSAP) measured by enzyme-linked immunosorbent assay [18] (ELISA; interassay CV 511%).”
MethodSelf-citation
Cited by
Items 201–204 of 204
Endothelial RANK signaling triggers bone marrow inflammagingPreprint
Kobayashi, Y., Iwamoto, R., Takahashi, T., Ishida, M., He, Z., Murakami, K., Hara, T., Ganbaatar, B., Yamagami, H., Endo, I., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10285332/v1
Recent progress in the biomarkers of peripheral artery disease
Chen, B.-W., Chen, W., Yu, X.-H., & Wang, G. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.122864
Meraci, B., Ercan, N., Yıldırım, E. A., Akgül, Z., & Yis, Ö. M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15197752
Metadata
- Authors
- Khosla, S., Arrighi, H. M., Melton, III, Atkinson, E. J., O'Fallon, W. M., Dunstan, C., & Riggs, B. L.
- Affiliations
- Mayo Clinic (US)
- Amgen (United States) (US)
- Venue
- Osteoporosis International
- Published
- 2002-05-01
- Volume
- 13
- Issue
- 5
- Pages
- 394-399
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- OpenAlex
- W2034959911
- Cited by
- 205
- References
- 19
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 6 · 2023: 3 · 2022: 3 · 2021: 5 · 2020: 3 · 2019: 5 · 2018: 3 · 2017: 6 · 2016: 5 · 2015: 4 · 2014: 6 · 2013: 9 · 2012: 10
- FWCI
- 6.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Osteoporosis International (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR 27065, R01AR027065)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- osteoprotegerin, sex steroids, testosterone, estrogen, bone turnover markers, bone mineral density, bone resorption, menopause, aging, sex differences, RANK ligand, bone loss, bone homeostasis
- MeSH terms
- Adult, Aged, Aged, 80 and over, Aging, Enzyme-Linked Immunosorbent Assay, Estradiol, Female, Glycoproteins, Humans, Male, Middle Aged, Sex Characteristics, Testosterone, Bone Remodeling, Premenopause, Postmenopause, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Statistics, Nonparametric, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.